235 related articles for article (PubMed ID: 33000505)
1. Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection.
Levinson T; Dahan A; Novikov A; Paran Y; Berman J; Ben-Ami R
Mycoses; 2021 Jan; 64(1):78-85. PubMed ID: 33000505
[TBL] [Abstract][Full Text] [Related]
2. The impact of the fluconazole trailing effect on the persistence of Candida albicans bloodstream infection when treated with fluconazole.
Lin SY; Huang HY; Chang LL; Wang YL; Chen TC; Chang K; Tu HP; Lu PL
Clin Microbiol Infect; 2024 Jul; 30(7):945-950. PubMed ID: 38527614
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
van Hal SJ; Chen SC; Sorrell TC; Ellis DH; Slavin M; Marriott DM
J Antimicrob Chemother; 2014 Aug; 69(8):2210-4. PubMed ID: 24788656
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Ben-Ami R; Olshtain-Pops K; Krieger M; Oren I; Bishara J; Dan M; Wiener-Well Y; Weinberger M; Zimhony O; Chowers M; Weber G; Potasman I; Chazan B; Kassis I; Shalit I; Block C; Keller N; Kontoyiannis DP; Giladi M;
Antimicrob Agents Chemother; 2012 May; 56(5):2518-23. PubMed ID: 22314534
[TBL] [Abstract][Full Text] [Related]
7. Association of fluconazole pharmacodynamics with mortality in patients with candidemia.
Baddley JW; Patel M; Bhavnani SM; Moser SA; Andes DR
Antimicrob Agents Chemother; 2008 Sep; 52(9):3022-8. PubMed ID: 18591269
[TBL] [Abstract][Full Text] [Related]
8. Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia.
Al Thaqafi AH; Farahat FM; Al Harbi MI; Al Amri AF; Perfect JR
Int J Infect Dis; 2014 Apr; 21():5-9. PubMed ID: 24468816
[TBL] [Abstract][Full Text] [Related]
9. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
10. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Torres HA; Kontoyiannis DP; Rolston KV
Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
[TBL] [Abstract][Full Text] [Related]
11. Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study.
Zilberberg M; Yu HT; Chaudhari P; Emons MF; Khandelwal N; Shorr AF
Crit Care; 2014 Oct; 18(5):590. PubMed ID: 25358521
[TBL] [Abstract][Full Text] [Related]
12. A Risk Score for Fluconazole Failure among Patients with Candidemia.
Ostrosky-Zeichner L; Harrington R; Azie N; Yang H; Li N; Zhao J; Koo V; Wu EQ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264843
[TBL] [Abstract][Full Text] [Related]
13. The association between fluconazole dose and MIC with mortality and persistence in candidemia.
Ghanem-Zoubi N; Qasum M; Khoury J; Zorbavel D; Arnon M; Geffen Y; Paul M
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1773-1780. PubMed ID: 31197619
[TBL] [Abstract][Full Text] [Related]
14. Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.
Brosh-Nissimov T; Ben-Ami R
Clin Microbiol Infect; 2015 Nov; 21(11):1011-7. PubMed ID: 26183300
[TBL] [Abstract][Full Text] [Related]
15. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, risk factors, treatment and outcome of Candida bloodstream infections because of Candida albicans and Candida non-albicans in two district general hospitals in the United Kingdom.
Raja NS
Int J Clin Pract; 2021 Jan; 75(1):e13655. PubMed ID: 32869497
[TBL] [Abstract][Full Text] [Related]
18. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
19. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
[TBL] [Abstract][Full Text] [Related]
20. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
